Neuroblastoma: Global Pipeline Review, H1 2018 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Neuroblastoma - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 30, 15, 3, 44, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 14 and 3 molecules, respectively.

Companies Mentioned

  • AstraZeneca Plc
  • Autolus Ltd
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • Bexion Pharmaceuticals LLC
  • Bio-Cancer Treatment International Ltd
  • BioLineRx Ltd
  • Biotec Pharmacon ASA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cielo Therapeutics Inc
  • Cleveland BioLabs Inc
  • EnGeneIC Ltd
  • Epizyme Inc
  • Errant Gene Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • GC Pharma
  • GlaxoSmithKline Plc
  • ID Pharma Co Ltd
  • Ignyta Inc
  • Ipsen SA
  • Juno Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Loxo Oncology Inc
  • MacroGenics Inc
  • MediaPharma SRL
  • Merck & Co Inc
  • Morphogenesis Inc
  • Novartis AG
  • Pfizer Inc
  • Sapience Therapeutics Inc
  • Syros Pharmaceuticals Inc

Key Topics Covered

  1. Introduction
  2. Neuroblastoma - Overview
  3. Neuroblastoma - Therapeutics Development
  4. Neuroblastoma - Therapeutics Assessment
  5. Neuroblastoma - Companies Involved in Therapeutics Development
  6. Neuroblastoma - Drug Profiles
  7. Neuroblastoma - Dormant Projects
  8. Neuroblastoma - Discontinued Products
  9. Neuroblastoma - Product Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/lrqkrz/neuroblastoma?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs, Brain Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs, Brain Cancer Drugs